Onconetix, Inc. Cost of Revenue
Onconetix, Inc. (ONCO) reported Cost of Revenue of $12.82 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement
us-gaap:CostOfRevenue · last filed 2026-08-13
- Onconetix, Inc. cost of revenue for the quarter ending 2026-06-30 was $12.82K, a 64.39% decline year-over-year.
- Onconetix, Inc. cost of revenue for the quarter ending 2026-03-31 was $23.11K, a 58.58% decline year-over-year.
- Onconetix, Inc. cost of revenue for the quarter ending 2025-12-31 was $55.91K, a 7.51% increase year-over-year.
- Onconetix, Inc. cost of revenue for the quarter ending 2025-09-30 was $34.76K, a 88.47% decline year-over-year.
- Onconetix, Inc. cost of revenue for fiscal 2025 was $182.46K, a 87.58% decline from fiscal 2024.
- Onconetix, Inc. cost of revenue for fiscal 2024 was $1.47M, a 23.90% increase from fiscal 2023.
- Onconetix, Inc. cost of revenue for fiscal 2023 was $1.19M.
| Period end | Cost of Revenue 3 month | Cost of Revenue 6 month | Cost of Revenue 9 month | Cost of Revenue 12 month |
|---|---|---|---|---|
| 2026-06-30 | $12.82K 10-Q · filed 2026-08-13 | $35.93K 10-Q · filed 2026-08-13 | $91.84K derived: sum of 3 quarters · filed 2026-08-13 | $126.60K derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $23.11K 10-Q · filed 2026-05-13 | $79.02K derived: sum of 2 quarters · filed 2026-05-13 | $113.78K derived: sum of 3 quarters · filed 2026-05-13 | $149.77K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $55.91K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-13 | $90.67K derived: sum of 2 quarters · filed 2026-03-13 | $126.66K derived: sum of 3 quarters · filed 2026-08-13 | $182.46K 10-K · filed 2026-03-13 |
| 2025-09-30 | $34.76K 10-Q · filed 2025-11-13 | $70.75K derived: sum of 2 quarters · filed 2026-08-13 | $126.55K 10-Q · filed 2025-11-13 | $178.55K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $35.99K 10-Q · filed 2026-08-13 | $91.79K 10-Q · filed 2026-08-13 | $143.80K derived: sum of 3 quarters · filed 2026-08-13 | $445.24K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $55.80K 10-Q · filed 2026-05-13 | $107.81K derived: sum of 2 quarters · filed 2026-05-13 | $409.25K derived: sum of 3 quarters · filed 2026-05-13 | $1.01M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $52.01K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-13 | $353.45K derived: sum of 2 quarters · filed 2026-03-13 | $957.59K derived: sum of 3 quarters · filed 2026-03-13 | $1.47M 10-K · filed 2026-03-13 |
| 2024-09-30 | $301.44K 10-Q · filed 2025-11-13 | $905.58K derived: sum of 2 quarters · filed 2025-11-13 | $1.42M 10-Q · filed 2025-11-13 | |
| 2024-06-30 | $604.13K 10-Q · filed 2025-08-14 | $1.12M 10-Q · filed 2025-08-14 | ||
| 2024-03-31 | $511.43K 10-Q · filed 2025-06-12 | |||
| 2023-12-31 | $1.19M 10-K · filed 2025-06-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| HCW Biologics Inc. (HCWB) | United States | $0.004B | -6.15 |
| REVELATION BIOSCIENCES, INC. (REVB) | United States | $0.004B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |